Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Securitize’s subsidiary completes SEC investment adviser registration, expanding tokenization infrastructure deployment

Securitize’s subsidiary completes SEC investment adviser registration, expanding tokenization infrastructure deployment

ForesightNewsForesightNews2026/07/27 13:25
Show original

Foresight News reported, citing CoinDesk, that the tokenization infrastructure company Securitize’s subsidiary, Securitize Capital, has completed its registration as an investment adviser with the US SEC. Previously, Securitize already held multiple regulatory licenses, including those for broker-dealer, alternative trading system (ATS), transfer agent, and fund administration; this new registration further enriches its compliant business framework. Securitize stated that the new license will provide broader support for serving more asset management firms and institutional investors exploring on-chain investment strategies. The company has already established partnerships with asset management institutions such as BlackRock, Apollo, KKR, and VanEck, and is responsible for issuing BlackRock's BUIDL tokenized money market fund, while also cooperating with the New York Stock Exchange to build tokenized securities trading infrastructure.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma